Find a Physician

Email this profile
Portrait View Larger

Cornelia L. Dekker, M.D.

Academic Appointments

  • Professor (Research) of Pediatrics (Infectious Diseases)

Key Documents

Contact Information

  • Clinical Offices
    Pediatric Infectious Diseases 300 Pasteur Dr G312 MC 5208 Stanford, CA 94305
    Tel Work (650) 724-4437 Fax (650) 725-8153
  • Academic Offices
    Personal Information
    Email Tel (650) 724-4437
    Alternate Contact
    Nancy Greguras Administrative Associate Tel Work (650) 498-6227
    Not for medical emergencies or patient use

Professional Overview

Clinical Focus

  • Pediatric Infectious Disease
  • Vaccine Clinical Trials
  • Vaccine Safety
  • Influenza, Human

Academic Appointments

Administrative Appointments

  • Medical Director, Stanford-LPCH Vaccine Program (1999 - present)
  • Member, Department of Pediatrics Research Advisory Committee (2009 - present)
  • Member, Department of Pediatrics Administrative Advisory Committee (2008 - 2009)
  • IRB Reviewer, Stanford Administrative Panel on Human Subjects in Medical Research, Panel 3 (2002 - present)
  • Member, Stanford GCRC Advisory Committee (2006 - present)

Honors and Awards

  • Junior Faculty Award, SmithKlein Beecham (07/05/00-07/04/02)
  • Excellence in Teaching, Stanford Univ. School of Medicine (06/23/08)

Boards, Advisory Committees, Professional Organizations

  • Chair, NIH DMID SMC: Phase I Study to Determine the Human Infectious Doses Causing 50% Infection with the GII.4 Norovirus Filtrate, CIN 1 (2013 - present)
  • Chair, NIH DMID SMC: Phase I Study to Determine the Human Infectious Dose Causing 50% Infection with the GII.2 Snow Mountain Norovirus Filtrate, SNM (2013 - present)
  • Member, NIH DMID SMC: 13-Valent Pneumococcal Conjugate Vaccine in Adults 55 through 74 Years of Age (2012 - present)
  • Member, External Data Monitoring Committee for Study Drug: ACC-001 (vanutide cridificar) a joint development project for an Alzheimer’s disease vaccine between Pfizer and Janssen (2011 - present)
  • Member, HIV Vaccine Trial Network Safety Monitoring Board (Chair 2014-present) (2009 - present)
  • Member, NIH DMID SMC Evaluation of a Challenge Pool of Norwalk Virus Inocula in Human Subjects (2008 - present)
View All 16professional activities and affiliations of Cornelia Dekker

Professional Education

Board Certification: Pediatrics, American Board of Pediatrics (1981)
Medical Education: Michigan State University MI (1976)
Fellowship: Duke University Medical Center NC (1982)
Residency: Duke University Medical Center NC (1979)
Internship: Duke University Medical Center NC (1977)
B.S.: Michigan State University, Microbiology & Public Health, Human Clinical Medicine (1973)
View All 7



Graduate and Fellowship Program Affiliations

Scientific Focus

Current Research and Scholarly Interests

The overarching theme of our research activities is human response to natural virus infection and to vaccines. We have conducted several studies of adult, toddler and infant immune response to initial infection with human cytomegalovirus (HCMV). Our largest was a project in which we screened 20,000 newborn infants at Stanford, El Camino and Santa Clara Valley Hospitals for evidence of congenital HCMV infection. Those infants identified as being infected were enrolled into a 3-year prospective study for medical, audiology and immunology screening. The hearing screening portion was designed to identify, as early as possible, infants who develop sensorineural hearing loss as a result of this infection.

A second area of clinical research is supported by Dr. Mark Davis' NIH-funded CCHI U19 project entitled "Protective Mechanisms Against Pandemic Respiratory Virus" and the newer HIPC U19 project entitled "Vaccination and Infection: Indicators of Immunological Health and Responsiveness". To provide samples for the lab projects we immunize children and adults (including elderly) with one of four different, licensed influenza vaccines (Fluzone, Fluzone high-dose, Fluzone Intradermal or FluMist) to study in detail the immune response to immunization given by various routes. Blood samples collected from study subjects are analyzed for influenza-specific B and T-cell responses as well as gene expression studies and cytokine analyses. Our latest studies have focused on genetic vs. environmental influences by enrolling fraternal and identical twins. Under the HIPC U19, we are conducting a study of the shingles vaccine in twins and non-twin adults for a close examination of T-cell responses. We also have conducted a study of natural influenza infection for the past 3 years in children and adults to collect NP swabs and blood samples in collaboration with researchers in the Greenberg lab who study how B cells and T cells respond to influenza virus infection.

Our group also is funded as part of the Vaccine Treatment and Evaluation Units by NIH through our collaborators at Vanderbilt University. We have conducted studies of avian, novel H1N1 and seasonal influenza vaccines and a new malaria vaccine under this subcontract. A study of a new DNA vaccine against influenza is ongoing under sponsorship by EMMES Corporation and the Vaccine Research Center at NIH.

A fourth area of interest has been vaccine safety. Stanford was one of six designated Centers for Immunization Safety Assessment (CISA) sponsored by the CDC for a 10 year period. The network provided consultation to CDC on evaluation and treatment of adverse events following immunization with licensed vaccines, developed protocols to study certain events that occur following immunization (including hypersensitivity reactions, safety of live viral vaccines in immunodeficient children, genetics study of Guillain-Barre syndrome patients). We also collaborate with Dr. Greg Enns on a study of the safety of influenza vaccine and its metabolic effects in patients with the MELAS mtDNA polymorphisms.

For further information about ongoing studies, please refer to our website at


Publication tag cloud

Publication Topics

View All 69

Stanford Medicine Resources:

Footer Links: